Navigation Links
Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Date:5/3/2012

rporate website at www.lexpharma.com through May 31, 2012.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of telotristat etiprate (LX1032), LX1033, LX2931, LX4211, and LX7101 including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of telotristat etiprate (LX1032), LX1033, LX2931, LX4211, and LX7101.  This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of telotristat etiprate (LX1032), LX1033, LX2931, LX4211, and LX7101 and preclinical and clinical development of it
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
4. Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
5. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Lexicon Announces Commencement of Rights Offering to Stockholders
7. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
10. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
11. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Ill. , July 28, 2015 Today,s ... on par with their levels of clinical excellence. Today ... Annual Meeting & Clinical Lab Expo, Sysmex is announcing ... a comprehensive and intuitive ecosystem that will help laboratories ... key areas, Sysmex aims to add even more value ...
(Date:7/28/2015)... 2015 Research and Markets ... "Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019" ... therapeutics market to grow at a CAGR of 1.09% ... the present scenario and the growth prospects of the ... calculate the market size, the report considers revenue generated ...
(Date:7/28/2015)... , July 28, 2015   DigiPath Labs ... DIGP), is combining efforts with True North Laboratory of ... Romer Labs , a leading global supplier of diagnostic ... utilizing Romer Labs, rapid diagnostic test kits ... in cannabis. "This joint effort is expected ...
Breaking Medicine Technology:Sysmex Moves Beyond a Better Box 2Sysmex Moves Beyond a Better Box 3Sysmex Moves Beyond a Better Box 4Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market 2DigiPath Labs Partners with Romer Labs to Validate Food-Borne Pathogen and Mycotoxin Testing Solutions for Cannabis 2DigiPath Labs Partners with Romer Labs to Validate Food-Borne Pathogen and Mycotoxin Testing Solutions for Cannabis 3
... Get content from Novo Nordisk A/S at: ... Novo Nordisk announced on March 15 that the ... approved Victoza® for the treatment of type 2 ... the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue ...
... patients in China will gain access to Varian,s state-of-the-art ... center is acquiring a GammaMed® brachytherapy afterloader from Varian ... high dose rate afterloader supplied to Chinese hospitals by ... Jilin University No. 1 Hospital in Jilin will ...
Cached Medicine Technology:Video from Novo Nordisk A/S available on thenewsmarket.com: Novo Nordisk Receives Approval for Victoza in China 2First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom ... cardiology is the identification of individuals with active yet undetected sub-clinical disease, who ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for identifying Top Doctors, has based its selection process on the foundation of ... in their medical specialties, in any area of medicine and in any part ...
(Date:7/28/2015)... ... 2015 , ... One of the most common running related ... plantar fasciitis . Zensah, the Miami-based compression brand, offers a product that can ... the Zensah Ankle Support’s primary benefits include helping support the ankle, reduce swelling, ...
(Date:7/28/2015)... ... July 28, 2015 , ... Nurses across all settings ... up to 57 million Americans may need mental health services (SAMHSA, 2013) and the ... Psychiatric-mental health RNs are one of the largest workforces who provide care to ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 3Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 4
... A novel gene called rumi regulates Notch signaling by ... Notch protein that extends outside a cell, said researchers ... Brook University in New York in a report that ... governed by the Notch protein determines cell fate determination ...
... works for allergic asthma, rhinitis, conjunctivitis or insect ... If you have allergic asthma, rhinitis, conjunctivitis or ... candidate for allergy shots, also known as immunotherapy. ... of Allergy, Asthma & Immunology. , "Immunotherapy is ...
... MYL ),today announced that it intends to appeal ... for the District of Columbia against Mylan and its ... of the,pending Lorazepam and Clorazepate antitrust cases. The first ... disclosed, in June 2005, a jury in the district ...
... Society of Plastic Surgeons (ASPS) today addressed concerns,regarding ... events following,a recent petition from a consumer group., ... U.S. Food and Drug,Administration (FDA) implement labeling changes ... one million people have been treated with BOTOX ...
... Unland, President of the,Chicago-based Health Capital Group, urged hospitals, ... their existing debt instruments, their,obligations and their capital and ... Problems with some major banks and bond insurers have ... do so for some time to come,resulting in both ...
... no medical benefit; heart expert calls it ,second-line, ... The controversy surrounding the highly promoted cholesterol-lowering drug ... they would review the medication,s effectiveness, but only ... debate began earlier this month when preliminary results ...
Cached Medicine News:Health News:Notch-ing glucose into place 2Health News:Allergy Shots Are Effective Treatment for Symptoms 2Health News:Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation 2Health News:ASPS Addresses Concerns Regarding BOTOX Treatments 2Health News:Health Capital Group Warns of Fallout to Hospitals From the Subprime Mortgage Crisis and Urges Hospitals to Immediately Reassess Existing Debt Structures and Capital Financing Plans 2Health News:FDA Will Wait for Trial Results on Vytorin 2Health News:FDA Will Wait for Trial Results on Vytorin 3
... advanced 16 to 64 channel sleep diagnostic ... 16 to 64 channel sleep diagnostic collection ... sleep event recording or post recording. The ... recorded during sleep events including current number ...
Aurora is a powerful Windows-based digital PSG instrument providing complete data acquisition, recording and review capabilities in one flexible package. The Aurora offers the most feature-packed PSG...
... gold-ball electrodes in a double-horn assembly ... electrode is in a ball and ... Supporting bone clamp design simplifies three ... braided, Teflon-coated wires terminate in a ...
... Medelec Synergy N-EP provides total testing ... smaller instrument is driven by space ... testing equipment on the move ... 2, 5, or 10-channel Medelec Synergy ...
Medicine Products: